Switchable Living Drug Shrinks Tumors in Resistant Melanoma
Two early trials of an engineered tumor-fighting cell therapy found responses in two-thirds of 15 patients at the chosen dose, without the harsh drug IL-2.
Switchable Living Drug Shrinks Tumors in Resistant Melanoma
SPRIZ: The Molecular Pillar That Sets Mitochondria’s Inner Spacing
Digital Twins of the Immune System in Pregnancy
2026 Nobel Prize in Physiology or Medicine: How Optogenetics Lets Light Control the Brain
How to Choose the Right Storage Conditions for Biological Samples
Small Intestine Absorption and Nutrient Uptake
Role of Digestive Enzymes in Human Digestion
Viral Lung Infection and Its Impact on Lung Health
Lung Volumes and Capacities in Human Respiration
Breathing Mechanism and Respiratory Rhythm